Skip to Content

Research & Funding

Past Other NCI & NIH InitiativesRSS

This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • Innovations in Biomedical Computational Science and Technology Initiative (SBIR [R43/R44]) (PAR-07-160)
    Innovations in Biomedical Computational Science and Technology Initiative (STTR [R41/R42]) (PAR-07-161)

    BISTI targets support for fundamental research in biomedical computing science and technology as well as the development and application of new biocomputing tools or technologies for a particular area(s) of scientific opportunity in biomedical research.

    Programs may target one or multiple areas of biomedical computing that will enable progress in biomedical research. Examples of data types that could be considered include but are not limited to genomic sequences, biomedical images, qualitative descriptors for health and social science, remote sensing and geospatial images, and pathway data.

    URLs: (SBIR) (STTR)

  • Shared Instrumentation Grant Program (S10) (NCRR) (PAR-07-105)

    • Release Date: December 06, 2006
    • Application Receipt Date: March 21, 2007
    • Expiration Date: March 22, 2007
    • Contacts:

      Marjorie A. Tingle, Ph.D., NCRR, Phone 301-435-0772, Email:

    The NCRR Shared Instrument Grant (SIG) program solicits applications from groups of NIH-supported investigators to purchase or upgrade commercially available instruments that cost at least $100,000. The maximum award is $500,000. Types of instruments supported include confocal and electron microscopes, biomedical imagers, mass spectrometers, DNA sequencers, biosensors, cell sorters, X-ray diffraction systems, and NMR spectrometers among others.


  • NOT-FD-06-001: Notice of Availability of Funds to Support Clinical trials on the Safety and Effectiveness of Products for Rare Diseases (FDA)

    • Release Date: November 27, 2006
    • Application Receipt Date: February 7, 2007
    • Expiration Date: N/A
    • Contacts:

      Debra Y. Lewis, O.D., (; Phone: 301-827-0059

    The Food and Drug Administration's (FDA) Office of Orphan Products Development (OPD) is pleased to announce the availability of funds for fiscal year (FY) 2008 grant awards to support clinical trials on the safety and effectiveness of products for rare diseases and conditions. Contingent on availability of FY 2007 and FY 2008 funds, it is anticipated that $14.2 million will be available for new applications, competing awards, and non competing continuation awards. These studies are intended to provide acceptable data to the FDA that will substantially contribute to the approval of new products, or new indications for already marketed products. In the FDA OPD grants program, products for rare diseases and conditions (orphan products) are defined as drugs, biologics, medical devices, and medical foods indicated to treat or diagnose a rare disease or condition with a prevalence of fewer than 200,000 people in the United States.

    See Notice in NIH Guide:NOT-FD-06-001

  • PAR-06-540: Cancer Education Grants Program (R25)

    • Release Date: August 30, 2006
    • Application Receipt Date: Multiple dates, see announcement
    • Expiration Date: March 2, 2008
    • Contacts:

      Lester S. Gorelic, Ph.D., Phone: 301-496-8580, Email:

    This Funding Opportunity Announcement (FOA) uses the NIH Research Education (R25) grant mechanism to support the following types of programs: innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; short courses to update cancer research scientists in new scientific methods, technologies and findings; training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health and community applications (delivery).

    Because the nature and scope of the proposed research education program will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

    The total project period for an application submitted in response to this funding opportunity may not exceed five years. Direct costs are limited to $300,000 per year.

    See full description in NIH Guide:PAR-06-540

  • PA-06-533: Functional Links between the Immune System, Brain Function and Behavior (R21) (NIMH, NCI, NIA, NIAMS, NIBIB, NIDA, NINDS)

    • Release Date: August 22, 2006
    • Application Receipt Date: Multiple dates, see announcement.
    • Expiration Date: September 2, 2008
    • Contacts:

      Paige McDonald, Ph.D., Phone: 301-435-5037, Email:

    The potent effects of neuroimmune molecules in the brain are mediated through multiple signaling pathways. However, details regarding the extent, routes, or mechanisms whereby immune signaling affects the brain in either normal conditions or during immune challenge and inflammation are largely unexplored. The purpose of this FOA is to identify research opportunities that may help to bridge the gap in understanding how immune cells and their mediators affect brain development, function and behaviors related to cognition and mood.

    See full description in NIH Guide:PA-06-533

  • PA-06-461, PA-06-462, & PA-06-463: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21, R33, & R21/R33) (NIMH, NIA, NIAAA, NIBIB, NIDA, NINDS)

    • Release Date: August 07, 2006
    • Application Receipt Date: Multiple dates, see announcement
    • Expiration Date: July 2, 2009
    • Contacts:

      4 different contacts for the different ICs

    This FOA is intended to stimulate the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. The widespread availability and use of these radioligands are expected to: 1) accelerate research on identifying and characterizing the neural circuits and pathways implicated in the pathophysiology of brain disorders (especially mental and behavioral disorders, substance abuse, neurodegenerative disorders, and pediatric brain disorders) and brain changes with age, and 2) facilitate the identification of new therapeutic targets and the development of new compounds as potential therapeutic agents. Research partnerships among investigators in both academia and pharmaceutical and biotechnology industries are encouraged to more rapidly develop PET and SPECT radiotracers and apply neuroimaging in drug discovery, biomarker development//qualification, and pathophysiological studies.

    Molecular targets for which radioligands (agonist and antagonist ) are needed include, but are not limited to, the following. Please contact program staff to determine program priorities and molecular targets of interest to specific NIH Institutes or refer to the Internet addresses listed above for each of the participating NIH Institutes.

    • Receptors: adenosine; adrenergic: alpha 1, alpha 2; cannabinoid: CB1, CB2; corticotropin releasing hormone: CRF R1, CRF R2; dopamine: D1, D3, D4, D5; estrogen; GABA A subunits; GABA ion channel; GABA B; glutamatergic, glycine site; metabotropic glutamate subtypes; muscarinic subunits; neurokinin receptors: NK1, NK2, NK3; neuronal nicotinic receptor subunits: alpha 7 & alpha 4 beta 2; NMDA subunits; opioid receptors: mu, delta, kappa; serotonin: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, 5-HT5, 5-HT6, 5-HT7; voltage gated ion channels: Ca, Na, K - M current proteins.
    • Transporters: vesicular ACh; GABA; glutamate; glycine; glutamine; NET; VMAT, excitatory amino acid transporters.
    • Markers for glia ,glial activation, and glial cell death.
    • Enzymes: choline acetyltransferase; dopamine beta-hydroxylase; GABA transaminase; glutamic acid decarboxylase; glutaminergic; phosphodiesterases; tyrosine hydroxylase.
    • Intracellular targets: abnormal proteins or protein aggregates including synuclein, prion protein, amyloid or tau deposition; diacylglycerol; gene expression/transcription markers; markers of neurogenesis or neuronal cell death; markers of mitochondrial function; lipid metabolism; neuroinflammatory markers: cytokines, COX inhibitors; peptidases; phosphatases; phospholipases; protein kinases; stem cells.

    See full description in NIH Guide: R21 PA-06-461; R33 PA-06-462; R21/R33 PA-06-463

  • PA-06-512: Mentored Clinical Scientist Research Career Development Award (K08)

    • Release Date: August 07, 2006
    • Application Receipt Date: Multiple dates, see announcement
    • Expiration Date: September 2, 2009
    • Contacts:

      David J. Eckstein, Ph.D. (NCI), Phone: 301-496-8580, Email:

    The Mentored Clinical Scientist Research Career Development Award (K08) represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award (K23).

    An award is for a period of 3 to 5 years and provides support for salary and research-related costs. The amount funded as salary for a career development award varies among the NIH participating Institutes and Centers (ICs). Therefore, the applicant is strongly advised to contact the relevant IC for any distinct guidelines, requirements, and allowable funds (

    See full description in NIH Guide:PAR-06-512

  • PAR-06-475: Nanoscience and Nanotechnology in Biology and Medicine(R21) (Multiple ICs)

    • Release Date: July 10, 2006
    • Application Receipt Date: August 18, 2006
    • Expiration Date: August 19, 2006

    This funding opportunity announcement (FOA) is aimed at enhancing nanoscience and nanotechnology research approaches that have the potential to make valuable contributions to biology and medicine. The purpose of this initiative is to stimulate cross-cutting, integrative research in these fields of science and technology. In particular, this initiative invites research on: i) the creation and use of structures, devices and systems that have novel properties and functions because of their small size, that may be used to achieve a fundamental understanding of biological processes and /or contribute to disease detection, therapy, or prevention; ii) conception and fabrication of devices, that will effectively detect and analyze nanoscale entities of relevance to biomedicine; and iii) the study of biological systems at the nanoscale for the explicit purpose of using that information to develop nanotechnologies and nanostructured materials that will in turn benefit biology and medicine. The research projects that will be most responsive to this FOA will require interdisciplinary collaborations among investigators with expertise in a range of disciplines, including but not limited to engineering, physics, chemistry, cellular and molecular biology, materials and computer science. Applications submitted in response to this PA may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.

    See full description in NIH Guide:PAR-06-475

  • NOT-OD-06-081: NIH Offers Commercialization Assistance Program to SBIR Phase II Awardees

    • Release Date: July 10, 2006
    • Application Receipt Date: July 31, 2006
    • Expiration Date: N/A

    The CAP consists of training workshops, individual mentoring and consulting sessions, and it culminates with an opportunity for companies to present their business opportunities to potential investors and strategic partners at the NIH Life Sciences Showcase. Participation is free; however, selected participants are responsible for their travel expenses to attend two required workshops and the optional showcase. Detailed program information, eligibility requirements, and application instructions are available at The deadline for submitting an application is July 31, 2006. Approximately 125 companies will be selected to participate in this year's NIH CAP and will be notified by August 14, 2006.

    See full description in NIH Guide:NOT-OD-06-08

  • NIH-PAR-06-075: Nanoscience and Nanotechnology in Biology and Medicine

    • Release Date: July 10, 2006
    • Application Receipt Date: August 18, 2006
    • Expiration Date: August 19, 2006
    • Contacts:

      Jeff Schloss, Ph. D., NHGRI, Phone: 301-435-5538, Email:

    See full description in NIH Guide:NIH PAR-06-475